Bristol Myers Squibb Co (BMY): Capital Expenditures
$1.31B
Year ended 2025-12-31
$1.34B
Trailing 12 months to 2026-06-30
+5.5%
3-year compound annual growth
+11.7%
5-year compound annual growth
+4.8%
10-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.31B | +5.0% | 2026-02-11, From 2025-01-01 |
| 2024-12-31 | $1.25B | +3.2% | 2026-02-11, From 2024-01-01 |
| 2023-12-31 | $1.21B | +8.1% | 2026-02-11, From 2023-01-01 |
| 2022-12-31 | $1.12B | +14.9% | 2025-02-12, From 2022-01-01 |
| 2021-12-31 | $973.00M | +29.2% | 2024-02-13, From 2021-01-01 |
| 2020-12-31 | $753.00M | -9.9% | 2023-02-14, From 2020-01-01 |
| 2019-12-31 | $836.00M | -12.1% | 2022-02-09, From 2019-01-01 |
| 2018-12-31 | $951.00M | -9.9% | 2021-02-10, From 2018-01-01 |
| 2017-12-31 | $1.05B | -13.2% | 2020-02-24, From 2017-01-01 |
| 2016-12-31 | $1.22B | +48.2% | 2019-02-25, From 2016-01-01 |
| 2015-12-31 | $820.00M | +55.9% | 2018-02-13, From 2015-01-01 |
| 2014-12-31 | $526.00M | -2.0% | 2017-02-21, From 2014-01-01 |
| 2013-12-31 | $537.00M | -2.0% | 2016-02-12, From 2013-01-01 |
| 2012-12-31 | $548.00M | +49.3% | 2015-02-13, From 2012-01-01 |
| 2011-12-31 | $367.00M | -13.4% | 2014-02-14, From 2011-01-01 |
| 2010-12-31 | $424.00M | -41.9% | 2013-02-15, From 2010-01-01 |
| 2009-12-31 | $730.00M | -22.4% | 2012-02-17, From 2009-01-01 |
| 2008-12-31 | $941.00M | +11.6% | 2011-02-18, From 2008-01-01 |
| 2007-12-31 | $843.00M | n/a | 2010-02-19, From 2007-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $1.31B | +5.0% |
| Abbott Laboratories (ABT) | 2025-12-31 | $2.17B | -1.6% |
| AbbVie Inc. (ABBV) | 2025-12-31 | $1.21B | +24.6% |
| Pfizer Inc (PFE) | 2025-12-31 | $2.63B | -9.6% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $4.11B | +21.9% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $4.83B | +9.2% |
| Teva Pharmaceutical Industries Ltd (TEVA) | 2025-12-31 | $501.00M | +0.6% |
| Regeneron Pharmaceuticals, Inc. (REGN) | 2025-12-31 | $898.40M | +18.9% |
| Viatris Inc (VTRS) | 2025-12-31 | $378.80M | +16.2% |
Compare BMY, ABT, ABBV, PFE side by side · Screen every company in Pharmaceutical Preparations ↗